Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Cancer Oncology

Internal Medicine

Pathology And Forensic Medicine

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1182/blood-2024-197938